PARSIPPANY, N.J. — Actavis Inc. has begun shipping oxymorphone hydrochloride extended-release tablets, an opioid painkiller, in dosages of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg.
The company said Thursday that its product is the generic equivalent to the previously marketed formulation of Endo Health Solutions’ Opana ER, which was voluntarily withdrawn from sale in 2012.
Actavis said it previously received approval for and is now marketing oxymorphone hydrochloride extended-release tablets in strengths of 7.5 mg and 15 mg.
The company added that it’s currently a defendant in a lawsuit filed by Endo claiming that Actavis’ oxymorphone hydrochloride extended-release product infringes on certain Endo patents.
Opana ER is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring around-the-clock opioid treatment for an extended period of time.
